Factors Influencing Immunotherapy Outcomes in Cancer: Sarcopenia and Systemic Inflammation
Cancer Control · 2024
DOI: 10.1177/10732748241302248 ↗Kurz gefasst
Fachartikel in der Zeitschrift Cancer Control, 2024. Verfasst von Enes Ucgul und 5 weiteren Autor:innen. Beteiligte Einrichtung: Division of Endocrinology and Metabolism, Etlik City Hospital, Ankara, Turkey. Hauptthemen laut MEDLINE: Sarcopenia, Inflammation, Neoplasms, Immunotherapy. Die Arbeit wurde bisher 22-mal zitiert (Crossref) und nennt 62 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0).
Abstract (Originalsprache)
Background
Immunotherapy has shown promise in treating various subtypes of metastatic cancers, but many patients are frail and may have compromised immune systems, which can influence treatment outcomes. Sarcopenia, a condition characterized by loss of muscle mass and systemic inflammation, is a potential factor that may negatively impact the response to immunotherapy. However, more data must be collected on the extent of its influence. Therefore, this study aims to investigate the effects of sarcopenia, systemic inflammation, and Eastern Cooperative Oncology Group Performance Status (ECOG PS) on the response to immunotherapy.
Methods
We enrolled 100 patients treated with immune checkpoint inhibitors between 2015 and 2021 who underwent computed tomography of the abdomen before the first immunotherapy dose. This study was conducted retrospectively. Gender-specific thresholds were used for the diagnosis of sarcopenia. C-reactive protein (CRP), erythrocyte sedimentation rate, neutrophil-to-lymphocyte ratio (NLR), platelet-to-lymphocyte ratio (PLR), albumin, and lactate dehydrogenase (LDH) were used as markers of systemic inflammation. Systemic inflammatory markers and sarcopenia were assessed using univariable and multivariable analyses for overall survival (OS) and progression-free survival (PFS).
Results
Sarcopenia was found to be a significant prognostic factor associated with poor PFS (HR, 2.33; 95% confidence interval [CI], 1.45-3.74; P < 0.001). In addition, hypoalbuminemia was identified as a significant prognostic factor for predicting OS (HR, 2.10; 95% CI, 1.21-3.66; P = 0.008).
Conclusions
Closer monitoring and prevention of sarcopenia may enhance both OS and PFS. Additionally, our composite model may assist oncologists in predicting responses to immunotherapy more accurately. However, further prospective studies are needed to validate these findings.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Division of Endocrinology and Metabolism, Etlik City Hospital, Ankara, Turkey.
- Department of Medical Oncology, Elazığ Fethi Sekin City Hospital, Elazığ, Turkey.
- Department of Radiation Oncology, Gulhane Training and Research Hospital, Ankara, Turkey.
- Department of Radiology, Hacettepe University Faculty of Medicine, Ankara, Turkey.
- Department of Medical Oncology, Hacettepe University Cancer Institute, Ankara, Turkey.
ORCID-Profile: Enes Ucgul
Zitieren
APA
Ucgul, E., Guven, D. C., Ucgul, A. N., Ozbay, Y., Onur, M. R., & Akin, S. (2024). Factors Influencing Immunotherapy Outcomes in Cancer: Sarcopenia and Systemic Inflammation. Cancer Control. https://doi.org/10.1177/10732748241302248
Vancouver
Ucgul E, Guven DC, Ucgul AN, Ozbay Y, Onur MR, Akin S. Factors Influencing Immunotherapy Outcomes in Cancer: Sarcopenia and Systemic Inflammation. Cancer Control. 2024. doi:10.1177/10732748241302248
BibTeX
@article{Ucgul2024,
author = {Ucgul, Enes and Guven, Deniz Can and Ucgul, Aybala Nur and Ozbay, Yakup and Onur, Mehmet Ruhi and Akin, Serkan},
title = {Factors Influencing Immunotherapy Outcomes in Cancer: Sarcopenia and Systemic Inflammation},
journal = {Cancer Control},
year = {2024},
doi = {10.1177/10732748241302248}
}
EUVIMED